Ruxolitinib cream

Ruxolitinib cream is licensed for the treatment of non‐segmental vitiligo with facial involvement in adolescents (≥12 years old) and adults. This article summarises its mechanism of action, the clinical trial evidence of efficacy and its place in therapy.

Authors

Publication Details

Journal
Prescriber
Published
2024-09-01
DOI
https://doi.org/10.1002/psb.2152
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ruxolitinib cream

Steve Chaplin
Prescriber
Chronic Lymphocytic Leukemia Research
article

Ruxolitinib cream

Steve Chaplin
article en

Abstract

Ruxolitinib cream is licensed for the treatment of non‐segmental vitiligo with facial involvement in adolescents (≥12 years old) and adults. This article summarises its mechanism of action, the clinical trial evidence of efficacy and its place in therapy.

PrescriberVol. 35(5)
Openalex Percentile: Top 75%
Chronic Lymphocytic Leukemia Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Ruxolitinib cream — Steve Chaplin · Prescriber (2024) | TGRS Research Map | TGRS